Allergy Therapeutics ends contract with Lincoln Medical

Allergy Therapeutics has terminated its agreement with Lincoln Medical for the distribution rights of Anapen in a number of countries, following a recall of the drug in the UK.

Allergy Therapeutics has terminated its agreement with Lincoln Medical for the distribution rights of Anapen in a number of countries, following a recall of the drug in the UK.

The pharmaceutical company said Lincoln Medical undertook a voluntary recall of all unexpired units of Apapen, an adrenaline for injection, as a precautionary measure.

It followed a potential problem with delivery time and volume of the dosage of the drug.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Allergy Therapeutics has decided to terminate its agreement with Lincoln Medical after careful consideration.

Manuel Llobet, Chief Executive Officer, said: "The board has decided that terminating the arrangement with Lincoln Medical is in the best interests of the company. Although disappointing to lose a product line, the Anapen contract did deliver a net positive return to the company.

"Diversification into other geographies and product in-licensing opportunities continue to be explored in line with the group's strategy for growth."

Anapen is an autoinjector of epinephrine commonly used by people with severe allergies and a risk of anaphylactic shock because they can be self-administered and are fast-acting.

RD